Patents by Inventor Oliver Sander

Oliver Sander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250161444
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g. an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 16, 2024
    Publication date: May 22, 2025
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Publication number: 20250161443
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 16, 2024
    Publication date: May 22, 2025
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Publication number: 20250161445
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 16, 2024
    Publication date: May 22, 2025
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Publication number: 20240398779
    Abstract: Described herein are methods of treating early or intermediate age-related macular degeneration with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof. e.g. iptacopan hydrochloride.
    Type: Application
    Filed: September 2, 2022
    Publication date: December 5, 2024
    Inventors: Arnaud Armel Olivier CHARIL, Oliver SANDER, Nadia ZAKARIA
  • Publication number: 20230321232
    Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
    Type: Application
    Filed: December 19, 2022
    Publication date: October 12, 2023
    Inventors: Charis PAPAVASSILIS, Oliver SANDER, Tomohiro SHIMA, Susumu KITAMURA
  • Publication number: 20230321231
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 2, 2022
    Publication date: October 12, 2023
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Patent number: 11534490
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: December 27, 2022
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Patent number: 11351253
    Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter cilia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: June 7, 2022
    Assignee: NOVARTIS AG
    Inventors: Charis Papavassilis, Oliver Sander, Tomohiro Shima, Susumu Kitamura
  • Publication number: 20210162044
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 3, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Publication number: 20210113688
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Publication number: 20200171147
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 4, 2020
    Inventors: Achim GUETTNER, Matthias MACHACEK, Charis PAPAVASSILIS, Oliver SANDER
  • Publication number: 20200085945
    Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter cilia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 19, 2020
    Inventors: Charis PAPAVASSILIS, Oliver SANDER, Tomohiro SHIMA, Susumu KITAMURA
  • Patent number: 10583190
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 10, 2020
    Assignee: NOVARTIS AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Patent number: 10434172
    Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: October 8, 2019
    Assignee: Novartis AG
    Inventors: Charis Papavassilis, Oliver Sander, Tomohiro Shima, Susumu Kitamura
  • Publication number: 20170304439
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 26, 2017
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Patent number: 9717791
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: August 1, 2017
    Assignee: Novartis AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
  • Publication number: 20160193333
    Abstract: The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter alia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.
    Type: Application
    Filed: August 13, 2014
    Publication date: July 7, 2016
    Applicant: Novartis AG
    Inventors: Charis PAPAVASSILIS, Oliver SANDER, Tomohiro SHIMA, Susumu KITAMURA
  • Publication number: 20130202610
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: October 7, 2011
    Publication date: August 8, 2013
    Applicant: Novartis AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassillis, Oliver Sander
  • Patent number: 7932743
    Abstract: A programmable integrated circuit performs an initial partial configuration of the programmable integrated circuit in response to receiving an activation signal. In this way, the programmable integrated circuit enables an initial functionality of the programmable integrated circuit. The programmable integrated circuit then performs a subsequent partial configuration of the programmable integrated circuit for enabling additional functionality of the programmable integrated circuit. In some embodiments, the programmable integrated circuit receives an input signal indicating a stimulus in an environment of the programmable integrated circuit and determines based on the input signal whether to perform the subsequent partial configuration of the programmable integrated circuit or generate a power down signal for powering down the programmable integrated circuit without performing the subsequent partial configuration.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: April 26, 2011
    Assignee: Xilinx, Inc.
    Inventors: Rodney Stewart, Michael Huebner, Juan J. Noguera Serra, Robert P. Esser, Jurgen Becker, Oliver Sander, Matthias Traub, Joachim H. Meyer